Royalty Pharma Sub-Manager, LLC

CIK 2081668 · View on SEC EDGAR ↗

Portfolio value
$241.9M
#5,834 of 9,443 by 13F value · top 61.8%
Positions
4
As of
June 30, 2026

Portfolio value QoQ: +40.0% 13F does not disclose cash

Top 10 holdings weight
100.00%
Top 25 holdings weight
100.00%
Positions above 1%
4
Effective number of positions
3.8

Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)

Turnover Q2 2026: 17.66% Est. buys $54,091,515 · sells $36,615,386

New positions
1
Increased
0
Decreased
0
Closed
1
On this page

Sector breakdown

Healthcare
77.6%
Other/Unmapped
22.4%

Full portfolio 4 positions

Type Streak 8Q trend
CYTK Cytokinetics, Incorporated - Common Stock $83,519,594 34.52% 980,392 $18,901,957
BCAX Bicara Therapeutics Inc. - Common Stock $60,611,247 25.05% 2,388,150 $13,922,914
Unknown issuer (CUSIP: 482931102) $54,091,515 22.36% 2,455,357 Up ×1
BHVN Biohaven Ltd. Common Shares $43,695,224 18.06% 2,936,507 $18,852,375

Biggest new bets

New positions opened this quarter, largest first.

Security Value Shares % of portfolio
Unknown issuer (CUSIP: 482931102) $54,091,515 2,455,357 22.36%

Top movers (QoQ)

Security Action Shares Δ Value Δ
CYTK Price move only +0 +$18.9M
BHVN Price move only +0 +$18.9M
BCAX Price move only +0 +$13.9M

Exited positions

Includes corporate events (mergers, delistings) — not all exits are sells

Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.

SecurityQuarter Shares before Value before Price since exit
BCRX June 30, 2026 3,846,154 $36,615,386 -0.6%